Dr. Aditya Bardia

Aditya Bardia, MD, MPH, FASCO

Professor, Department of Medicine, Division of Hematology/Oncology
Director of Translational Research Integration





Medical Oncology, Johns Hopkins Kimmel Cancer Center, Baltimore, MD, 2011


College of Public Health, University of Iowa, Iowa City, IA, 2004
All India Institute of Medical sciences (AIIMS), New Delhi, India, 2002


Internal Medicine, Mayo Clinic School of Medicine, Rochester, MN, 2008

Scientific Interests

Dr. Bardia's research goal is to advance the field of translational oncology and improve clinical outcomes of patients with cancer. He is the principal investigator of several clinical trials investigating precision therapeutics, and he has led the clinical development of novel therapies, including sacituzumab govitecan (IMMU-132), the first ADC approved for patients with metastatic TNBC, elacestrant, the first oral SERD approved for patients with metastatic HR+ breast cancer. Dr. Bardia led the clinical development of blood-based biomarkers, such as CTCs and ctDNA, as "liquid biopsy" for identification of novel targets, therapy selection, monitoring, and understanding resistance to guide therapeutic development.

Highlighted Publications

Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K. Sacituzumab Govitecan hziy in refractory metastatic triplenegative breast cancer. N Engl J Med. 2019 Feb 21;380(8):741-751. PMID: 30786188

Bardia A, Tolaney SM, Hurvitz SA Loirat D, Punie K, Oliveira M, Rugo HS, Brufsky A, Kalinsky K, Cortés J, O'Shaughnessy J, Dieras VC, Carey LA, Gianni L, Piccart M, Loibl S, Goldenberg D, Hong Q, Olivo MS, Itri LM, Rugo H. Sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). N Engl J Med. 2021 Apr 22;384(16):1529-1541. PMID: 33882206.

Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret- Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, García Sáenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortés J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative advanced breast cancer: Results from the randomized phase III EMERALD trial. J Clin Oncol. 2022 Oct 1;40(28):3246- 3256. PMID: 35584336.

Yu M*, Bardia A*, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013. 339(6119):580-4. *= equal contribution. PMID: 25013076.

Coates JT, Sun S, Leshchiner I, Thimmiah N, Martin EE, McLoughlin D, Danysh BP, Slowik K, Jacobs RA, Rhrissorrakrai K, Utro F, Levovitz C, Denault E, Walmsley CS, Kambadakone A, Stone JR, Isakoff SJ, Parida L, Juric D, Getz G, Bardia A*, Ellisen LW*. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to Sacituzumab Govitecan in Triplenegative breast cancer. Cancer Discov. 2021 Oct;11(10):2436-2445. . *= equal contribution PMID: 34404686.